Online inquiry

IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ5679MR)

This product GTTS-WQ5679MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GPNMB gene. The antibody can be applied in Breast Cancer research.

Specifications
Product type	mRNA
Modified bases	N1-Methylpseudo-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_001005340.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	10457
UniProt ID	Q14956

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5679MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ10034MR	IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	L19-131 I
GTTS-WQ6885MR	IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	E-6011
GTTS-WQ12728MR	IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	OMP-305B83
GTTS-WQ3416MR	IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	aALB03
GTTS-WQ13674MR	IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	RC18
GTTS-WQ4605MR	IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	BMS-986015
GTTS-WQ4105MR	IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	BI-204
GTTS-WQ8110MR	IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	HGS-ETR2

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST